HIF-1α Cardioprotection in COVID-19 Patients.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. HIF-1α Pathway in COVID-19: A Scoping Review of Its Modulation and Related Treatments.International journal of molecular sciences · 2025
   Article
2. Classification and regulatory interactions of key transcription factors in COVID-19.Frontiers in cellular and infection microbiology · 2025
   Review
3. Anti-infection effects of heparin on SARS-CoV-2 in a diabetic mouse model.Zoological research · 2023
   Article
4. Mechanism of COVID-19-Induced Cardiac Damage from Patient, In Vitro and Animal Studies.Current heart failure reports · 2023
   Review
5. Targeting 2-Oxoglutarate-Dependent Dioxygenases Promotes Metabolic Reprogramming That Protects against Lethal SARS-CoV-2 Infection in the K18-hACE2 Transgenic Mouse Model.ImmunoHorizons · 2023
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

5 authors.

Funding

Abstract

PubMed holds no abstract for this paper.